The platelet-derived growth factor receptor as a therapeutic target.
Several small molecule tyrosine kinase inhibitors that block the epidermal growth factor receptor and vascular endothelial growth factor receptor function are among the many recently developed targeted anticancer therapeutic agents. Increasing evidence indicates that inhibition of other tumor stromal targets could provide additional and possibly synergistic antitumor effects. This article focuses on the platelet-derived growth factor receptor as one such potential target.
Lewis
Nancy L
NL
Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. nancy.lewis@fccc.edu
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D017479:Receptors, Platelet-Derived Growth Factor